Abstract
Patients with systemic lupus erythematosus (SLE) now benefit from an improved life expectancy compared with 50 years ago. However clinicians and researchers have observed that the occurrence of co-morbidities is of increasing importance when assessing outcome of the disease long term. Some important co-morbidities in SLE include cardiovascular disease, osteoporosis and cancer. It is important to understand these conditions, since they represent a significant proportion of the morbidity and mortality associated with SLE. It is increasingly possible for clinicians to appropriately screen for these conditions and treatment strategies to reduce the effects of these complications are being developed for cardiovascular disease and metabolic bone disease. This chapter reviews the recent literature on cardiovascular disease, metabolic bone disease including osteoporosis and cancer risk in SLE.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Sources
Cardiovascular Disease
Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford). 2007;46(6):983–8.
Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol. 2005a;19(5):823–38.
Bruce IN. ‘Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford). 2005b;44(12):1492–502.
Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66(2):208–14.
Elliott JR, Manzi S. Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2009;23(4):481–94.
Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005;25(9):1776–85.
Kaplan MJ. Premature vascular damage in systemic lupus erythematosus. Autoimmunity. 2009;42(7):580–6.
McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2428–37.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.
Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.
Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010;36(1):81–97. viii.
Volkmann ER, Grossman JM, Sahakian LJ, et al. Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(2):258–65.
Metabolic Bone Disease
Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(1):111–3.
Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2044–50.
Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009;44(5):734–43.
Toloza SM, Cole DE, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19(1):13–9.
Amital H, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7.
Cancer Risk
Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52(5):1481–90.
Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case cohort study. Ann Rheum Dis. 2008;67:74–9.
Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, Cason J. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57(4):619–25.
Lofstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007;66:1627–32.
King JK, Costenbader KH. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin’s lymphoma (NHL). Clin Rheumatol. 2007;26(9):1491–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gayed, M., Yee, CS., Bernatsky, S., Gordon, C. (2012). Co-morbidities in Systemic Lupus Erythematosus. In: Schur, P., Massarotti, E. (eds) Lupus Erythematosus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1189-5_18
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1189-5_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1188-8
Online ISBN: 978-1-4614-1189-5
eBook Packages: MedicineMedicine (R0)